TY - JOUR
T1 - Preadmission diabetes-specific risk factors for mortality in hospitalizedpatients withdiabetes and coronavirus disease 2019
AU - Agarwal, Shivani
AU - Schechter, Clyde
AU - Southern, Will
AU - Crandall, Jill P.
AU - Tomer, Yaron
N1 - Funding Information:
The authors greatly appre-ciate the efforts of their fellow health care workers and support staff at MMC for providing outstanding patient care at considerable personal risk on the front lines of this pandemic. The authors express their solidarity with those who are or have been ill with COVID-19 and their families.
Publisher Copyright:
© 2020 by the American Diabetes Association.
PY - 2020/10
Y1 - 2020/10
N2 - OBJECTIVE To examine whether HbA1c, outpatient diabetes treatment regimen, demographics, and clinical characteristics are associated with mortality in hospitalized patients with diabetes and coronavirus disease 2019 (COVID-19). RESEARCH DESIGN AND METHODS This was a retrospective cohort analysis of patients with diabetes hospitalized with confirmed COVID-19 infection from 11 March to 7 May 2020 at a large academic medical center in New York City. Multivariate modeling was used to assess the independent association of HbA1c levels and outpatient diabetes treatment regimen with mortality, in addition to independent effects of demographic and clinical characteristics. RESULTS We included 1,126 hospitalized patients with diabetes and COVID-19 for analysis, among whom mean age was 68 years, 50% were male, 75% were Black, mean BMI was 30 kg/m2, 98% had type 2 diabetes, mean HbA1c was 7.5%, and 33.1% died. HbA1c levels were not associated with mortality in unadjusted or adjusted analyses, but an outpatient regimen with any insulin treatment was strongly predictive. Additionally, age, sex, and BMI interacted such that in all age categories, mortality was higher with increasing BMI in males compared with females. CONCLUSIONS In this large U.S. cohort of hospitalized patients with diabetes and COVID-19, insulin treatment, as a possible proxy for diabetes duration, and obesity rather than long-term glycemic control were predictive of mortality. Further investigation of underlying mechanisms of mortality and inpatient glycemic control is needed.
AB - OBJECTIVE To examine whether HbA1c, outpatient diabetes treatment regimen, demographics, and clinical characteristics are associated with mortality in hospitalized patients with diabetes and coronavirus disease 2019 (COVID-19). RESEARCH DESIGN AND METHODS This was a retrospective cohort analysis of patients with diabetes hospitalized with confirmed COVID-19 infection from 11 March to 7 May 2020 at a large academic medical center in New York City. Multivariate modeling was used to assess the independent association of HbA1c levels and outpatient diabetes treatment regimen with mortality, in addition to independent effects of demographic and clinical characteristics. RESULTS We included 1,126 hospitalized patients with diabetes and COVID-19 for analysis, among whom mean age was 68 years, 50% were male, 75% were Black, mean BMI was 30 kg/m2, 98% had type 2 diabetes, mean HbA1c was 7.5%, and 33.1% died. HbA1c levels were not associated with mortality in unadjusted or adjusted analyses, but an outpatient regimen with any insulin treatment was strongly predictive. Additionally, age, sex, and BMI interacted such that in all age categories, mortality was higher with increasing BMI in males compared with females. CONCLUSIONS In this large U.S. cohort of hospitalized patients with diabetes and COVID-19, insulin treatment, as a possible proxy for diabetes duration, and obesity rather than long-term glycemic control were predictive of mortality. Further investigation of underlying mechanisms of mortality and inpatient glycemic control is needed.
UR - http://www.scopus.com/inward/record.url?scp=85091469628&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091469628&partnerID=8YFLogxK
U2 - 10.2337/dc20-1543
DO - 10.2337/dc20-1543
M3 - Article
C2 - 32769128
AN - SCOPUS:85091469628
SN - 1935-5548
VL - 43
SP - 2339
EP - 2344
JO - Diabetes Care
JF - Diabetes Care
IS - 10
ER -